A picks-and-shovels precision medicine play that doesn't tend to grab headlines, CareDx (NASDAQ: CDNA) describes itself as "focused on better outcomes through personalized transplant surveillance." Its suite of offerings encompasses the spectrum of transplant medicine: waitlist management for patients, high-resolution donor matching, AI analysis for risk of transplant rejection, and diagnostic blood and urine testing for transplant failure and/or rejection.
And the company is dominating its field, thanks to its demonstrated ability to create and expand an entire ecosystem of testing and management systems across multiple transplant lines -- kidney, lung, heart, and soon, stem cells. Investors intrigued by larger peers such as Guardant Health (NASDAQ: GH) may want to consider CareDx as a better healthcare bargain at a fraction of the price.
Image Source: Getty Images.
For further details see:
Like Guardant Health? You'll Love CareDx